Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Idelalisib (Zydelig) is associated with a cumulative incidence of severe infections (grade 3 or higher) at 30.89% in patients receiving phosphoinositide 3-kinase (PI3K) inhibitor-based regimens, which includes pneumonia (3.01 to 8.45%), febrile neutropenia (2.68 to 10.80%), and sepsis (0.9 to 4.48%). This indicates a notable safety concern compared to other therapies.
• In comparative terms, the incidence of severe infections for idelalisib is higher than that for Bruton's tyrosine kinase (BTK) inhibitors (19.86%), second-generation anti-CD20 monoclonal antibodies (19.85%), and B-cell lymphoma 2 (BCL-2) inhibitors (17.49%), highlighting the need for enhanced infection management strategies in patients treated with idelalisib.
• The studies did not provide specific efficacy outcomes for idelalisib, focusing instead on the issue of acquired resistance without delineating effectiveness among various population types or subgroups, particularly in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
• The studies focus on patients with CLL and SLL, highlighting that the cumulative incidence of severe infections in this population is influenced by the type of targeted therapy, with idelalisib associated with a 30.89% incidence of grade 3 or higher infections, underscoring the necessity for vigilant infection surveillance and effective prophylactic strategies.